

REVIEW ARTICLE

Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants

Thomas Luger¹, Mark Boguniewicz², Warner Carr³, Michael Cork⁴, Mette Deleuran⁵, Lawrence Eichenfield⁶, Philippe Eigenmann⁷, Regina Fölster-Holst⁸, Carlo Gelmetti⁹, Harald Gollnick¹⁰, Eckard Hamelmann¹¹, Adelaide A. Hebert¹², Antonella Muraro¹³, Arnold P. Oranje^{14,15,16}, Amy S. Paller¹⁷, Carle Paul¹⁸, Luis Puig¹⁹, Johannes Ring²⁰, Elaine Siegfried²¹, Jonathan M. Spergel²², Georg Stingl²³, Alain Taieb²⁴, Antonio Torrelo²⁵, Thomas Werfel²⁶ & Ulrich Wahn²⁷

¹Department of Dermatology, University of Münster, Münster, Germany; ²Division of Pediatric Allergy-Immunology, Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine, Denver, CO, USA; ³Southern California Research, Mission Viejo, CA, USA; ⁴Academic Unit of Dermatology Research, Department of Infection and Immunity, The University of Sheffield, K Floor, The Medical School (RHH Tower), Sheffield, UK; ⁵Department of Dermatology, Aarhus University Hospital, Aarhus C, Denmark; ⁶Departments of Pediatrics and Medicine, University of California, San Diego School of Medicine, Rady Children's Hospital, San Diego, CA, USA; ⁷Pediatric Allergy Unit, Children's University Hospital, Geneva, Switzerland; ⁸Department of Dermatology, University Clinics of Schleswig-Holstein, Kiel, Germany; ⁹Department of Pathophysiology and Transplantation, University of Milan, Clinica Dermatologica, Fondazione I.R.C.C.S. Ca' Granda "Ospedale Maggiore Policlinico", Milan, Italy; ¹⁰Department of Dermatology & Venereology, Otto-von-Guericke University of Magdeburg, Magdeburg, Germany; ¹¹Allergy Center Ruhr, Ruhr-University Bochum, & Evangelisches Krankenhaus Bielefeld, Klinik für Kinder und Jugendmedizin, Bielefeld, Germany; ¹²Departments of Dermatology and Pediatrics, The University of Texas Medical School-Houston, Houston, TX, USA; ¹³Food Allergy Referral Centre, Department of Woman and Child Health, University Hospital of Padua, Padua, Italy; ¹⁴Department of Dermatology, Maasstad Hospital, Rotterdam, the Netherlands; ¹⁵Dermicis Skin Hospital, Alkmaar, the Netherlands; ¹⁶Intermedica Dermatology and Hair Clinic, Boxmeer, the Netherlands; ¹⁷Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; ¹⁸Dermatology Department, INSERM 1056, Paul Sabatier University, Larrey Hospital, Toulouse, France; ¹⁹Department of Dermatology, Hospital de la Santa Creu i Sant Pau & Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain; ²⁰Department of Dermatology and Allergology Biederstein, Christine Kühne-Center for Allergy Research and Education, Technische Universität München, Munich, Germany; ²¹Departments of Pediatrics and Dermatology, Saint Louis University School of Medicine, St. Louis, MO, USA; ²²Division of Allergy and Immunology, Department of Pediatrics, The Children's Hospital of Philadelphia, Perelman School of Medicine at University of Pennsylvania, Pennsylvania, PA, USA; ²³Department of Dermatology, Medical University of Vienna, Vienna, Austria; ²⁴Service de Dermatologie et Dermatologie Pédiatrique Centre de référence pour les maladies rares de la peau, INSERM 1035, Université de Bordeaux, Bordeaux, France; ²⁵Department of Dermatology, Hospital Niño Jesus, Madrid, Spain; ²⁶Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany; ²⁷Department of Pediatric Pneumology and Immunology, Charite, Berlin, Germany

To cite this article: Luger T, Boguniewicz M, Carr W, Cork M, Deleuran M, Eichenfield L, Eigenmann P, Fölster-Holst R, Gelmetti C, Gollnick H, Hamelmann E, Hebert AA, Muraro A, Oranje AP, Paller AS, Paul C, Puig L, Ring J, Siegfried E, Spergel JM, Stingl G, Taieb A, Torrelo A, Werfel T, Wahn U. Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants. *Pediatr Allergy Immunol* 2015; **26**: 306–315.

Keywords

atopic dermatitis; eczema; infants; paediatric; pimecrolimus; safety; tacrolimus; topical calcineurin inhibitors; topical corticosteroids

Correspondence

Thomas Luger, Department of Dermatology, University of Münster, Von-Esmarch-Str. 58, 48149 Münster, Germany
Tel.: +492518356504
Fax: +492518356522
E-mail: luger@uni-muenster.de

Accepted for publication 28 December 2014

DOI:10.1111/pai.12331

Abstract

Atopic dermatitis (AD) is a distressing dermatological disease, which is highly prevalent during infancy, can persist into later life and requires long-term management with anti-inflammatory compounds. The introduction of the topical calcineurin inhibitors (TCIs), tacrolimus and pimecrolimus, more than 10 yr ago was a major breakthrough for the topical anti-inflammatory treatment of AD. Pimecrolimus 1% is approved for second-line use in children (≥ 2 yr old) and adults with mild-to-moderate AD. The age restriction was emphasized in a boxed warning added by the FDA in January 2006, which also highlights the lack of long-term safety data and the theoretical risk of skin malignancy and lymphoma. Since then, pimecrolimus has been extensively investigated in short- and long-term studies including over 4000 infants (<2 yr old). These studies showed that pimecrolimus effectively treats AD in infants, with sustained improvement with long-term intermittent use. Unlike topical corticosteroids, long-term TCI use does not carry the risks of skin atrophy, impaired epidermal barrier function or enhanced percutaneous absorption, and so is suitable for AD treatment especially in sensitive skin areas. Most importantly, the studies of pimecrolimus in infants provided no evidence for systemic immunosuppression, and a

comprehensive body of evidence from clinical studies, post-marketing surveillance and epidemiological investigations does not support potential safety concerns. In conclusion, the authors consider that the labelling restrictions regarding the use of pimecrolimus in infants are no longer justified and recommend that the validity of the boxed warning for TCIs should be reconsidered.

Atopic dermatitis (AD) is a common skin disease during infancy and one which imposes a considerable burden on patients, their families and society. AD is one of the first diseases encountered during human life with 45% of cases occurring during the first 6 months. Its clinical presentation in infants typically involves the face, scalp, trunk and extensor surfaces of the extremities (1, 2). AD during infancy frequently persists into later life (3), is often associated with food allergy, and may be regarded as a presenting sign for the 'atopic march', which leads to the development of other atopic conditions such as asthma and allergic rhinitis (4, 5). AD is also associated with a considerable economic burden of up to \$3.8 billion each year in the USA alone (6).

The ultimate goal for the treatment of AD in infants is cure. Optimally, treatment should be initiated as early as possible to prevent the inside–outside loss of water (which leads to xerosis, fissures, pruritus and pain) and the outside–inside penetration of foreign substances (which leads to irritation and sensitization) (7, 8). Recent evidence suggests that normal appearing non-lesional skin also contains signs of subclinical inflammation, which treatments should aim to address to induce disease remission (9). Current AD treatments do not cure the disease, but instead focus on controlling and reducing its troublesome signs and symptoms. Given that AD is a chronic disease requiring treatment for many years or even decades, such treatments need to be safe and well tolerated.

Topical standard-of-care initial treatment for AD in infants includes emollients and topical corticosteroids (TCS). TCS are used on an as-needed basis to treat disease flares and may also be considered for proactive, intermittent, long-term maintenance treatment of previously affected skin to reduce the subsequent risk of relapses (9–15). The main drawbacks to TCS are their potential local and systemic side effects, including skin atrophy, impaired epidermal barrier function, and percutaneous absorption, possibly leading to impaired growth. These risks are of particular concern with prolonged continuous TCS use (16–20). Despite TCS being effective AD treatments, concern about potential side effects has led to widespread corticosteroid phobia and poor adherence to medication (21–23). In addition, few TCS have been approved for use in children under age 2 yr and then for only 3–4 wk.

Two topical calcineurin inhibitors (TCIs), pimecrolimus 1% cream (Elidel[®], Meda, Stockholm, Sweden) and tacrolimus 0.03% ointment (Protopic[®], Astellas, Tokyo, Japan), which selectively inhibit the synthesis of inflammatory cytokines released from T-cells and mast cells (24), have been available for the treatment of AD in patients aged 2 yr and older since 2000–2001. The use of TCIs is currently not approved in children below 2 yr of age in the USA and Europe, although

pimecrolimus is approved in patients aged 3 months and older in certain other countries such as Australia and Russia. In January 2006, the Food and Drug Administration (FDA) added a boxed warning ('black box') to the labels of these TCIs to emphasize that their long-term safety has not been established, to highlight the theoretical risk of skin malignancy and lymphoma with these treatments and to stress that their use in infants <2 yr of age is not recommended (25). This black box represents the first and only time that a warning was issued based on theoretical rather than proven safety concerns. The European Medicines Agency (EMA) also advised that TCIs should be used with caution and limited to second-line use following a safety review in March 2006.

Eight years after these warnings were issued, it is timely to re-evaluate the latest clinical efficacy and safety data on TCIs in infants to assess whether the restrictions regarding their use and the safety concerns highlighted in the boxed warnings are still justified. The primary focus of this article is on pimecrolimus rather than both TCIs, as only pimecrolimus has been extensively evaluated in studies including more than 4000 infants. To date, the efficacy and safety of tacrolimus have only been evaluated in one published open-label study of 50 infants with AD previously enrolled in a pharmacokinetic investigation (26, 27). Based on the results of a literature search and on expert opinion, the authors – a task force of expert paediatricians, dermatologists and allergists – developed consensus recommendations regarding the use of pimecrolimus in infants (defined as patients <2 yr of age) and on the safety of TCIs in general.

Clinical efficacy of pimecrolimus in infants

The favourable clinical efficacy of TCIs in AD is now well established and documented in several clinical trials. Accordingly, the treatment of AD in infants with pimecrolimus leads to a substantial reduction in disease flares (28, 29). Furthermore, studies in children and adolescents with AD have shown that long-term proactive maintenance therapy with TCIs reduces the risk of subsequent relapses (9, 30–32).

Comprehensive evidence for the clinical efficacy of pimecrolimus in infants comes from six studies that were conducted in more than 4000 patients (Table 1). Of note, the Petite study enrolled the largest population of infants with AD (i.e. 2418 patients) and followed them for the longest period of time ever studied (i.e. the first 5–6 yr of life). This open-label, parallel-group study randomized patients to treatment with pimecrolimus or TCS and had a 'real-world' design in which TCS were used according to their label and in which those treated with pimecrolimus were able to briefly use TCS if needed for an

Table 1 Overview of clinical studies of pimecrolimus in infants

Study	Age group	Interventions	Study design	Duration
Petite (33)	≥3–<12 months	Pimecrolimus (<i>n</i> = 1205) TCS (<i>n</i> = 1213)	Open-label, randomized, parallel group	5 yr
Study of the Atopic March (43)	3–18 months	Pimecrolimus (<i>n</i> = 546) Vehicle (<i>n</i> = 545)	Double-blind, randomized, parallel group Open-label extension with pimecrolimus	3 yr Up to 3 yr
Kapp et al. (2002) (28)	3–23 months	Pimecrolimus (<i>n</i> = 204) Vehicle (<i>n</i> = 47)	Double-blind, randomized, parallel group	1 yr
Papp et al. (2005) (29)	3–23 months	Pimecrolimus 2 yr (<i>n</i> = 76) Vehicle 1 yr; pimecrolimus 1 yr (<i>n</i> = 15)	One-year, open-label, non-comparative extension to Kapp et al. (28)	2 yr
Ho et al. (2003) (34)	3–23 months	Pimecrolimus (<i>n</i> = 123) Vehicle (<i>n</i> = 63)	Six-week randomized, double-blind phase followed by 20-wk open-label treatment with pimecrolimus	6 months
Kaufmann et al. (2004) (35)	3–23 months	Pimecrolimus (<i>n</i> = 129) Vehicle (<i>n</i> = 66)	Four-week randomized, double-blind phase followed by 12-wk open-label treatment with pimecrolimus and 4-wk follow-up	20 wk

TCS, topical corticosteroids.

acute flare (33). The TCS used varied according to the prescribing practices in different countries and included both low (e.g. hydrocortisone acetate) and medium potency (e.g. hydrocortisone butyrate) creams and ointments.

The clinical studies of pimecrolimus in infants have shown that this TCI leads to a rapid improvement in the signs and symptoms of AD. In the Petite study, 53% of pimecrolimus-treated infants had an overall Investigator's Global Assessment (IGA) score of 0 or 1 (indicating clear or almost clear of disease) after 3 wk of treatment (Fig. 1). Similarly, the median




Figure 1 Percentage of patients with treatment success in the Petite study (intent-to-treat population) (33). IGA, Investigator's Global Assessment; TCS, topical corticosteroids (low and medium potency TCS were allowed according to local prescribing practices).

total body surface area (TBSA) affected by AD decreased from 16% at baseline to 4% after 3 wk of pimecrolimus treatment (33). Other studies in infants have also reported rapid and significant efficacy benefits with pimecrolimus vs. vehicle such as reductions in the mean Eczema Area and Severity Index (EASI) score and improvements in pruritus (28, 34, 35). In these studies, the majority of the clinical benefit of pimecrolimus was observed within 2 wk of treatment. Improvements in pruritus were even more rapid, occurring within 2 days (35). Rapid improvements in AD have also been observed in subgroups of infants included in real-life observational studies of pimecrolimus (36, 37).

The initial improvement in AD observed in infants treated with pimecrolimus is sustained over the long term with a progressive increase in efficacy over time. The Petite study showed that 89% of pimecrolimus-treated infants had an overall IGA score of 0 or 1 after 5 yr of as-needed treatment (Fig. 1) and that the median TBSA affected by AD decreased to 0% after 1.5 yr (33). Similar short- and long-term disease improvements were reported for patients treated with TCS in this study (51% and 92% had an IGA of 0 or 1 after 3 wk and 5 yr, respectively). Moreover, the treatment of AD in infants with pimecrolimus in the Petite study was associated with a substantial steroid-sparing effect, with pimecrolimus-treated patients using TCS for a median of 7 days compared with 178 days in the TCS group over the 5-yr study. This confirms the reduced steroid requirement observed in previous shorter-term studies of pimecrolimus (28, 29).

Of particular note, pimecrolimus is effective at treating AD affecting sensitive skin areas such as the head and neck, which are common sites of disease presentation in infants. In the Petite study, 61% of pimecrolimus- and 62% of TCS-treated infants had a facial IGA score of 0 or 1 after only 3 wk of treatment, increasing to 97% in both groups at the end of the 5-yr study (33). Similarly, other studies have shown a greater reduction in the EASI score for the head and neck region with pimecrolimus vs. vehicle (34, 35).

The effective treatment of AD in infants with pimecrolimus translates into a beneficial impact on both the quality of life (QoL) of parents and of affected infants and children (38–40). This is important as AD has a major negative impact on the QoL of the affected child and their entire family, with the impairment in QoL being greater than or equal to that caused by other common childhood diseases such as asthma (41, 42).

The Study of the Atopic March examined whether early intervention with pimecrolimus was able to affect the atopic march in a large population of 1087 infants. The study design allowed patients to initiate rescue with a mid-potency TCS if 3 days of pimecrolimus led to no improvement. The study did not show any difference between the pimecrolimus and vehicle groups in the incidence of asthma, food allergy, allergic rhinitis and allergic conjunctivitis. However, the discontinuation rate in this study was unexpectedly high following the implementation of the FDA boxed warning, and early initiation of TCS may have obscured any differences between the groups (43).

Clinical safety of pimecrolimus in infants

There is convincing evidence that TCIs have a favourable safety profile without evidence for severe adverse events (AEs) (44, 45). Application site reactions, such as burning, erythema and pruritus, were reported in <1% of infants in a pooled analysis of data from clinical studies of pimecrolimus in these patients (46). The most common AEs reported in infants treated with pimecrolimus were typical childhood infections and ailments (e.g. nasopharyngitis, pyrexia, upper respiratory tract infections and bronchitis) with a similar incidence in the pimecrolimus and control groups, and discontinuations due to AEs were typically low (<2%) (28, 29, 33–35, 43, 46). An analysis of safety data from clinical trials and post-marketing surveillance (PMS) in infants showed no increase in the risk of systemic infections with pimecrolimus (relative risk vs. vehicle [95% CI] 1.015 [0.88–1.18]) (47). Similarly, there was no increased incidence of overall skin infections with pimecrolimus in a pooled analysis of data from short-term clinical studies in infants (relative risk vs. vehicle [95% CI] 1.118 [0.80–1.61]). The risk of bacterial, fungal, parasitic or viral skin infections in these studies was also not different in the pimecrolimus- or vehicle-treated groups (Fig. 2) (46).

The primary purpose of the Petite study was to thoroughly investigate the safety of pimecrolimus in infants given that certain infections and disorders were perceived as safety signals by the FDA on the basis of statistically non-significant increases in their incidence vs. vehicle control groups in two previous pivotal studies of pimecrolimus in infants (28, 34, 48). These differences could be explained by unbalanced randomization ratios in the previous studies resulting in substantially fewer patients in the vehicle groups. In the Petite study, the crude incidence and relative risk of the infections and disorders of primary clinical interest as defined by the FDA were not different in the pimecrolimus and TCS groups (Table 2) (33). There were also no differences in the time to first occurrence of these AEs. An additional statistical analysis of AE counts for frequent events (with a repeated Poisson regression model) showed that pimecrolimus-treated patients experienced signif-




Figure 2 Relative risk for skin infections in infants based on the incidence density rates (per 1000 patient-months of follow-up) in pimecrolimus and vehicle groups (46). CI, confidence interval.

icantly more events of bronchitis ($p = 0.02$), infected eczema ($p < 0.001$), impetigo ($p = 0.045$) and nasopharyngitis ($p = 0.04$). These increases were not considered clinically significant as the differences in the incidence of these events between groups were only 2–4%, and there was no statistical adjustment for the multiplicity of comparisons (33). Consequently, it was considered that the initial safety concerns from the FDA were not supported by the Petite study data.

Pharmacokinetic studies of pimecrolimus in infants and children up to 1 yr in duration demonstrated that there is minimal systemic exposure following topical application of this calcineurin inhibitor, even in patients with extensive disease (49–53). The minimal systemic absorption of topically applied pimecrolimus is due to its high molecular weight and lipophilicity (54). In contrast, even short-term topical application of hydrocortisone cream 1% (4–106 g) in children can result in an increase of cortisol plasma levels (55), although systemic exposure with more recently developed TCS such as fluticasone propionate is lower (56). The systemic absorption of TCS is highest on thin delicate skin sites such as the face where it is 300 times greater than the plantar aspect of the foot (57).

Importantly, the clinical studies of pimecrolimus in infants have not revealed any evidence of systemic immunosuppression. Extensive immunological assessments in the Petite study showed that pimecrolimus has no effect on the developing immune system. Neither pimecrolimus nor TCS had an effect

Table 2 Crude incidence and relative risk for AEs of primary clinical interest during the 5-yr Petite study (safety population) (33)

AE	Crude incidence (%)		Relative risk (95% CI)
	Pimecrolimus (n = 1205)	TCS (n = 1213)	
Influenza	6.9	5.7	1.346 (0.90–2.01)
Teething	14.9	14.9	1.179 (0.90–1.54)
Rhinitis	13.9	13.4	1.149 (0.86–1.54)
Nasopharyngitis	59.0	58.9	1.146 (1.01–1.30)
Gastroenteritis	28.2	27.1	1.146 (0.97–1.35)
Otitis media	34.7	31.7	1.135 (0.95–1.35)
Vomiting	22.5	21.3	1.116 (0.91–1.37)
Pyrexia	48.9	49.9	1.104 (0.96–1.26)
Diarrhoea	31.9	31.4	1.081 (0.92–1.27)
Cough	29.9	30.4	1.051 (0.87–1.27)
Pharyngitis	17.8	19.0	0.991 (0.75–1.31)
Hypersensitivity	2.0	1.9	0.989 (0.46–2.13)
Upper respiratory tract infection	32.0	31.2	0.937 (0.74–1.18)
Eye infection	0.3	0.3	0.871 (0.21–3.53)
Rhinorrhoea	6.8	6.8	0.804 (0.55–1.17)
Wheezing	5.6	5.3	0.752 (0.44–1.29)
Lower respiratory tract infection	3.7	4.5	0.749 (0.46–1.23)
Viral rash	3.0	4.1	0.719 (0.46–1.12)

AE, adverse event; CI, confidence interval; PIM, pimecrolimus 1% cream; TCS, topical corticosteroids.

Relative risk based on incidence density rate (pimecrolimus vs. TCS) and 95% CI was estimated from a Poisson regression model; incidence density ratio was calculated as 1000*total number of events/total monitoring time in months.

on T-cell or B-cell functions (33). Both the Petite study and a previous 2-yr study showed that the responses to childhood vaccinations (e.g. tetanus, diphtheria, measles, varicella and hepatitis B) were normal in pimecrolimus-treated infants with AD (33, 58).

A major concern of TCS, in particular when used for long-term treatment, is their potential to impair the epidermal barrier function and to cause skin atrophy. This is of special concern in infants as their epidermis is 20% thinner than that

of adults (59). TCIs do not affect epidermal barrier function or cause skin atrophy as, unlike TCS, they do not affect fibroblast function and collagen production (24, 60, 61). A summary of studies which have compared prolonged use of pimecrolimus and TCS on the skin barrier is shown in Table 3. In contrast to TCS, pimecrolimus had no effect on the epidermal structure and lipid lamellae (19). Both TCS and pimecrolimus improved stratum corneum integrity and cohesion as well as epidermal differentiation as measured by expression of filaggrin (19, 20).

Black box safety concerns

A compelling body of evidence now exists which does not support the safety concerns in the boxed warnings for TCIs. These warnings state that the long-term safety of TCIs has not been established and that rare cases of skin malignancy and lymphoma have been reported in patients using TCIs (48, 62). The warnings advise against long-term use of TCIs and emphasize that they are not indicated for use in children <2 yr of age. The labels also state that an increased risk of infections, lymphomas and skin malignancies has been observed following prolonged systemic use of calcineurin inhibitors in animal studies and in transplant patients after systemic immunosuppression (48, 62). In addition, the labels for TCIs highlight that their long-term safety has not been established beyond 1 yr of non-continuous use (48, 62). Although 'long term' is not specifically defined, the results of the Petite study have shown that 5 yr of intermittent pimecrolimus use is not associated with any of the mentioned safety signals (33).

More than 8 yr after the black box warning was introduced, there is still no evidence to suggest that TCIs cause skin malignancies or lymphoma (25). The systemic absorption that was documented in pharmacokinetic studies of these agents was far too low to cause a sustained systemic immunosuppression, which is required for the development of lymphomas (27, 49–53, 63, 64). Pre-clinical investigations initially suggested that exposure to high systemic levels of TCIs – much greater than can be achieved through topical application of humans – may result in the development of animal lymphomas (25, 48, 62). One 13-wk study showed that topical application of pimecrolimus in an ethanolic solution at 47 times the maximum recommended human dose (based on area under curve

Table 3 Effect of prolonged use of pimecrolimus and TCS on skin barrier

Property	Investigations	TCS effect	Pimecrolimus effect	References
Epidermal structure/thickness	Optical coherence tomography, ultrasound and histology	–ve	Neutral/?+ve	Aschoff et al. (2011) (18) Queille-Roussel et al. (2001) (17)
Lipid bilayers and lipid lamellae	Transmission electron microscopy	–ve	Neutral/?+ve	Jensen et al. (2009) (19)
Stratum corneum integrity and cohesion	Transepidermal water loss	+ve	+ve	Jensen et al. (2009) (19)
Epidermal differentiation	Expression of filaggrin and loricin	+ve	+ve	Jensen et al. (2009) (19) Jensen et al. (2012) (20)
Antimicrobial peptide expression	Enzyme-linked immunosorbent assay	–ve	?–ve	Jensen et al. (2011) (91)

TCS, topical corticosteroids.

comparisons) resulted in lymphoma in mice (25, 48). However, the relevance of this animal model to humans is questionable as mouse skin is much more permeable to molecules of the size of pimecrolimus than human skin (65). Furthermore, in long-term carcinogenicity studies, exposure to high doses of TCIs for 2 yr did not cause any skin cancers in mice and rats (25, 48, 62). Studies in hairless mice showed that both pimecrolimus and its vehicle enhanced UV photocarcinogenesis to a similar extent compared with no topical treatment as did both tacrolimus and its vehicle, and this forms the basis for the advice in their labels to avoid or minimize sunlight exposure (48, 62). After reviewing the available data, the European Dermatology Forum stated that there is no conclusive evidence to indicate that long-term topical application of TCIs in humans is photocarcinogenic (66). Furthermore, the hairless mouse model is no longer considered useful or recommended for photosafety testing in guidance from the FDA (67). All actives and vehicles studied in this model have resulted in an increased incidence of skin papilloma in rodents.

Prolonged systemic use of calcineurin inhibitors (cyclosporine and tacrolimus) in transplant recipients can lead to lymphoma and skin cancer due to the immunosuppressive mode of action of these drugs. The risk of lymphoma is related to the intensity of immunosuppression and the resulting inability to control Epstein–Barr virus (EBV) infection (68, 69). An increasing duration and cumulative dose of immunosuppressive medication also increases the risk of skin cancer in organ transplant patients with 40% experiencing skin cancer within the first 5 yr (70, 71). Estimates suggest that the level of systemic exposure which leads to lymphoma in organ transplant

recipients is 56- to 108-fold higher than can be achieved through topical application of calcineurin inhibitors (72).

The rare cases of lymphoma identified in TCI-treated patients do not have the clinical presentation and histology that characterize lymphomas due to immunosuppression (64, 73). The typical features of immunosuppression-related lymphomas include presentation as nodal or extranodal tumours, occurrence in unusual locations, polymorphic large cell histology, the presence of EBV genome in lymphoma cells, B-cell lymphomas occurring weeks, months or years after immunomodulatory therapy, and spontaneous regression after therapy is stopped (65, 73). It is possible that the patients identified as having lymphoma following TCI therapy may actually have had early forms of cutaneous T-cell lymphoma which were misdiagnosed as AD (65). Of note, no cases of lymphoma were reported in the 2418 patients randomized into Petite, although the study was not powered to specifically address the risk of malignancies (33).

Five epidemiological studies involving more than 6.5 million AD patients have not provided any evidence for an increased lymphoma risk with pimecrolimus (Table 4) (25, 74–77). In the largest of these studies, which included over 3.5 million AD patients, no cases of lymphoma were identified in pimecrolimus-treated patients (76). There is also no epidemiological evidence to suggest that TCI use is associated with non-melanoma or melanoma skin cancer (78). A case–control study involving a questionnaire mailed to 5000 adults with AD reported a decreased risk of non-melanoma skin cancer in patients using TCIs (adjusted odds ratio [95% CI] 0.54 [0.41–0.69]; Fig. 3) (79). A retrospective observational cohort study

Table 4 Epidemiological studies of the lymphoma risk following exposure to topical pimecrolimus

Study	Patients (n)	Design	Risk of lymphoma with pimecrolimus
Arellano et al. (2007) (74)	293,253	Nested case–control study using PharMetrics database	No increased risk of lymphoma with pimecrolimus treatment: adjusted odds ratio 0.8; 95% CI 0.4–1.6
Arana et al. (2011) (25)	625,915	Nested case–control study using PharMetrics database (extension of previous)	No increased risk of lymphoma with pimecrolimus treatment: adjusted odds ratio 0.76; 95% CI 0.54–1.08 No increased risk of T-cell lymphoma with pimecrolimus treatment: adjusted odds ratio 0.85; 95% CI 0.25–2.90
Hui et al. (2009) (75)	953,064	Retrospective cohort study using Kaiser Permanente California registries	No increased risk of T-cell lymphoma with pimecrolimus treatment: adjusted hazard ratio 2.32; 95% CI 0.89–6.07
Arellano et al. (2009) (76)	3,500,194	Nested case–control study using United Kingdom-based The Health Improvement Network database	No cases of lymphoma identified for pimecrolimus-treated patients
Schneeweiss et al. (2009) (77)	1,200,645	Propensity-score-matched cohort study using health insurance claims data	No increased risk of lymphoma with pimecrolimus compared with untreated patients: rate ratio 1.79; 95% CI 0.92–3.48 No increased risk of lymphoma with pimecrolimus compared with tacrolimus: rate ratio 1.16; 95% CI 0.74–1.82 No increased risk of lymphoma with pimecrolimus compared with TCS: rate ratio 1.15; 95% CI 0.49–2.72

CI, confidence interval; TCS, topical corticosteroids.




Figure 3 Odds ratio for non-melanoma skin cancer with topical calcineurin inhibitors (79). Odds ratio adjusted for age, gender, history of atopic dermatitis and history of non-melanoma skin cancer. CI, confidence interval.

of 953,064 AD patients did not show an association between melanoma and pimecrolimus use (adjusted hazard ratio [95% CI] 0.69 [0.37–1.28]) (75).

Post-marketing surveillance data and prospective registries have not identified an increased risk of lymphoma with TCIs (25). In the latest PMS data for pimecrolimus from 2012 to 2013, only two new cases of lymphoma have been identified (Meda data on file). In agreement with previous analyses, the small number of cases of lymphoma is below the expected background incidence in the population treated (25, 80). One previous analysis indicated that the incidence of lymphoma in pimecrolimus-treated patients identified in PMS is 54-fold less than that in the general population (0.41/100,000 vs. 22.0/100,000 patient-years of exposure, respectively) (80). Similarly, the Paediatric Eczema Elective Registry (PEER), which was initiated in 2004 to follow AD patients aged 2–17 yr treated with pimecrolimus, has only identified 4 cases of lymphoma over the past 10 yr. These cases are not the type of lymphoma that is typically related to immunosuppression.

There is currently no compelling clinical evidence to indicate that TCIs are associated with an increased risk of infections. AD patients have a pre-disposition to infections due to impairment of the skin barrier and cell-mediated immunity (81). There was no increased risk for overall skin infections in clinical studies of pimecrolimus in paediatric patients (relative risk vs. vehicle [95% CI] 0.78 [0.62–1.00]), although there may be a slightly increased risk for viral skin infections (1.80 [0.98–3.62]), in particular eczema herpeticum (47). In clinical studies of pimecrolimus in adult patients, there was no increase in the risk for overall skin infections (relative risk vs. vehicle [95% CI] 1.3 [0.9–1.8]) or viral skin infections (relative risk vs. vehicle [95% CI] 1.1 [0.7–2.0]) (44). Similarly, there is no evidence for an increase in the risk of cutaneous infections with long-term tacrolimus treatment (82).

Discussion

Currently, there is a paradox in the health care of infants with AD. The burden of disease is greatest in infants, and early disease control may prevent AD persistence into later life and possibly the atopic march to allergic rhinitis and asthma (83). However, only TCS are currently approved for use in infants. There is an unmet medical need for safe and effective

alternative therapies for AD in infants, including for application on sensitive skin areas such as the face where the disease commonly presents. Current labelling restrictions in the USA and Europe, however, prevent the use of TCIs in infants, despite the wealth of data demonstrating the clinical benefits and safety in this age group, especially of pimecrolimus.

The labelling restrictions for TCIs mean that many infants with AD who are uncontrolled with or intolerant to TCS have no treatment alternative. In addition, the long-term safety of TCS in infants has not been specifically studied and their use is restricted to 4 wk or less depending on the specific TCS and its country-specific label (25). In contrast, the long-term safety of pimecrolimus has been extensively investigated in clinical trials up to 5 yr in duration (33, 43, 46). This TCI does not cause skin atrophy and is recognized as an effective treatment for sensitive skin areas (17, 84). Currently, there are no valid safety concerns regarding the use of pimecrolimus to justify withholding it from infants.

The adverse effects of TCS encourage many parents of children with AD to use herbal creams. Many of these contain potent and super potent TCS, allergens and irritants and may be contaminated with pathogenic bacteria (85, 86). A large epidemiological study from the USA demonstrated an increased prevalence of AD in children who were treated with herbal and other alternative therapies (87). The use of pimecrolimus would be a much safer alternative to TCS than herbal topical products.

Since the introduction of the boxed warning for TCIs almost a decade ago, no compelling evidence has become available to support a causal link between their use and an increased risk of lymphoma or skin malignancy. Their safety has been comprehensively established through clinical studies, epidemiological investigations and PMS (25, 33, 43, 44, 74–77). Concerns regarding an increased risk for cancer after topical use of calcineurin inhibitors are theoretical only. Indeed, the evidence available to date indicates that the benefits of TCIs for the treatment of AD far outweigh any potential or theoretical risks. The safety of TCI therapy has also been widely recognized by many professional dermatology and paediatric organizations (15, 88–90).

The boxed warning for TCIs has had a far-reaching negative impact on paediatric patients with AD. Although only based on a theoretical risk, the decision to impose this warning has resulted in barriers to patient access and reimbursement for TCIs put in place by insurers and other payers, and a reluctance of physicians to prescribe TCIs due to factors such as an increased administrative burden and fear of litigation. This FDA warning has led to TCIs being withheld from infants with AD who have the greatest burden of disease, as well as denying other children and adults with AD access to effective therapies on the grounds of a theoretical, but unproven, safety risk. The warning has generated fear for patients (and their families) who are using or considering using TCIs. Finally, the black box has had a negative impact on clinical research programmes for TCIs in infants and paediatric drug development programmes in AD in general.

Consensus recommendations

Based on the current review of the literature and their clinical experience, the authors conclude that pimecrolimus cream and, based on more limited published reports, tacrolimus ointment, are safe and effective for the treatment of infants at least 3 months of age with AD. The authors consider the current labelling restrictions regarding TCI use in this population in Europe and the USA are no longer justified. In particular, TCIs are suitable for the treatment of sensitive skin areas in infants such as the face, which is a common site of disease presentation. Furthermore, based on the extensive evaluations into the safety of TCIs over the past 8 yr, the authors recommend that regulatory authorities should remove the current boxed warnings as this will allow AD patients to have access to effective medications with comprehensively established safety profiles.

Acknowledgments

Medical writing assistance in the preparation of this manuscript was provided by David Harrison, Medscript Communications. Funding for the manuscript and the advisory board meeting at which the recommendations were developed was provided by Gesellschaft zur Förderung der dermatologischen Forschung und Fortbildung e.V.

Conflicts of interest

Thomas Luger has given lectures for Astellas; and has given lectures, been an advisory board member, and conducted studies for Meda and Novartis. Mark Boguniewicz has previously been an investigator for Novartis and

Astellas-sponsored trials. Warner Carr has been a speaker for AZ; a speaker and advisor for Meda and TEVA, and an advisor for Merck. Michael Cork has been an advisory board member and given lectures for Meda, Novartis and Astellas; and has conducted studies for Novartis and Astellas. Mette Deleuran has been an advisory board member and given lectures for Meda and Astellas. Lawrence Eichenfield has been an investigator for Astellas (no honorarium) and a consultant for Valeant. Regina Fölster-Holst has given lectures and conducted studies for Astellas and Novartis. Carlo Gelmetti has been an advisor for La Roche-Posay; a speaker and an advisor for Bayer, Beiersdorf, and Pierre-Fabre; and a speaker for Meda. Adelaide Hebert has served on the DSMB for Novartis and Valeant; has given lectures for Astellas; and has received previous research funding from Astellas, Novartis, and GlaxoSmithKline with all monies paid to the University of Texas Medical School-Houston, Houston, Texas. Antonella Muraro has been a speaker and advisor for Meda; and an advisory board member for Nutricia. Arnold Oranje has been an advisor for La Roche Posay, GSK-Stiefel, Johnson & Johnson (advisory board study), Procter & Gamble and Pierre Fabres (Propranolol board); has given lectures in the last 2 years for Fagron, La Roche Posay, Meda and Texamed; and has received support for studies from Fagron bv, Molnlycke and Schering-Plough. Amy Paller has been an investigator for Astellas (no honorarium). Carle Paul was a former consultant and investigator for Novartis and Astellas. Luis Puig has been an advisory board member for Meda; and a former consultant and investigator for Novartis. Johannes Ring has been an advisory board member for Novartis, Astellas, and Meda. Elaine Siegfried has been a consultant for Valeant. Jonathan Spergel has been an advisory board member for Novartis. Alain Taieb received a grant from Astellas for an ongoing study in vitiligo. Antonio Torrelo has been an advisory board member and given lectures for Meda; and has given lectures for Astellas. Thomas Werfel has given lectures for Meda and Astellas. Ulrich Wahn has received a consultant fee from Bayer Consumer Care. Philippe Eigenmann, Harald Gollnick, Eckard Hamelmann and Georg Stingl report that they have no conflicts of interest to declare.

References

1. Watson W, Kapur S. Atopic dermatitis. *Allergy Asthma Clin Immunol* 2011; **7**(Suppl 1): S4.
2. Bieber T. Atopic dermatitis. *N Engl J Med* 2008; **358**: 1483–94.
3. Illi S, von Mutius E, Lau S, et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. *J Allergy Clin Immunol* 2004; **113**: 925–31.
4. Zheng T, Yu J, Oh MH, Zhu Z. The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. *Allergy Asthma Immunol Res* 2011; **3**: 67–73.
5. Kapoor R, Menon C, Hoffstad O, Bilker W, Leclerc P, Margolis DJ. The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. *J Am Acad Dermatol* 2008; **58**: 68–73.
6. Mancini AJ, Kaulback K, Chamlin SL. The socioeconomic impact of atopic dermatitis in the United States: a systematic review. *Pediatr Dermatol* 2008; **25**: 1–6.
7. Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. *J Allergy Clin Immunol* 2008; **121**: 1337–43.
8. Lee HJ, Lee SH. Epidermal permeability barrier defects and barrier repair therapy in atopic dermatitis. *Allergy Asthma Immunol Res* 2014; **6**: 276–87.
9. Tang TS, Bieber T, Williams HC. Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically useful? *J Allergy Clin Immunol* 2014; **133**: 1615–25.
10. Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. *Br J Dermatol* 2002; **147**: 528–37.
11. Peserico A, Städtler G, Sebastian M, Fernandez RS, Vick K, Bieber T. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. *Br J Dermatol* 2008; **158**: 801–7.
12. Berth-Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. *BMJ* 2003; **326**: 1367.
13. Glazenburg EJ, Wolkerstorfer A, Gerretsen AL, Mulder PG, Oranje AP. Efficacy and safety of fluticasone propionate 0.005% ointment in the long-term maintenance treatment of children with atopic dermatitis: differences between boys and girls? *Pediatr Allergy Immunol* 2009; **20**: 59–66.
14. Van Der Meer JB, Glazenburg EJ, Mulder PG, Eggink HF, Coenraads PJ. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic Dermatitis Study Group. *Br J Dermatol* 1999; **140**: 1114–21.
15. Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. *J Eur Acad Dermatol Venereol* 2012; **26**: 1045–60.
16. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. *J Am Acad Dermatol* 2006; **54**: 1–15.
17. Queille-Roussel C, Paul C, Duteil L, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy

- when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. *Br J Dermatol* 2001; **144**: 507–13.
18. Aschoff R, Schmitt J, Knuschke P, Koch E, Brautigam M, Meurer M. Evaluation of the atrophogenic potential of hydrocortisone 1% cream and pimecrolimus 1% cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography. *Exp Dermatol* 2011; **20**: 832–6.
 19. Jensen JM, Pfeiffer S, Witt M, et al. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. *J Allergy Clin Immunol* 2009; **124**: R19–28.
 20. Jensen JM, Scherer A, Wanke C, et al. Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis. *Allergy* 2012; **67**: 413–23.
 21. Aubert-Wastiaux H, Moret L, Le Rhun A, et al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. *Br J Dermatol* 2011; **165**: 808–14.
 22. Krejci-Manwaring J, Tusa MG, Carroll C, et al. Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. *J Am Acad Dermatol* 2007; **56**: 211–6.
 23. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. *Br J Dermatol* 2000; **142**: 931–6.
 24. Grassberger M, Steinhoff M, Schneider D, Luger TA. Pimecrolimus – an anti-inflammatory drug targeting the skin. *Exp Dermatol* 2004; **13**: 721–30.
 25. Siegfried EC, Jaworski JC, Hebert AA. Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. *Am J Clin Dermatol* 2013; **14**: 163–78.
 26. Mandelin JM, Rubins A, Remitz A, et al. Long-term efficacy and tolerability of tacrolimus 0.03% ointment in infants: a two-year open-label study. *Int J Dermatol* 2012; **51**: 104–10.
 27. Reitamo S, Mandelin J, Rubins A, et al. The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis. *Int J Dermatol* 2009; **48**: 348–55.
 28. Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. *J Allergy Clin Immunol* 2002; **110**: 277–84.
 29. Papp KA, Werfel T, Folster-Holst R, et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. *J Am Acad Dermatol* 2005; **52**: 240–6.
 30. Paller AS, Eichenfield LF, Kirsner RS, Shull T, Jaracz E, Simpson EL. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use. *Pediatrics* 2008; **122**: e1210–8.
 31. Thaci D, Reitamo S, Gonzalez Ensenat MA, et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. *Br J Dermatol* 2008; **159**: 1348–56.
 32. Ruer-Mulard M, Aberer W, Gunstone A, et al. Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis. *Pediatr Dermatol* 2009; **26**: 551–8.
 33. Sigurgeirsson B, Boznanski A, Todd G, et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. *Pediatrics* 2015; **135**: 597–606.
 34. Ho VC, Gupta A, Kaufmann R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. *J Pediatr* 2003; **142**: 155–62.
 35. Kaufmann R, Folster-Holst R, Hoger P, et al. Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants. *J Allergy Clin Immunol* 2004; **114**: 1183–8.
 36. Lübke J, Friedlander SF, Cribier B, et al. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. *Am J Clin Dermatol* 2006; **7**: 121–31.
 37. Ring J, Abraham A, de Cuyper C, et al. Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a > 2000 patient study. *J Eur Acad Dermatol Venereol* 2008; **22**: 195–203.
 38. McKenna SP, Whalley D, de Prost Y, et al. Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life. *J Eur Acad Dermatol Venereol* 2006; **20**: 248–54.
 39. Whalley D, Huels J, McKenna SP, Van Assche D. The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents' quality of life in the treatment of pediatric atopic dermatitis. *Pediatrics* 2002; **110**: 1133–6.
 40. Staab D, Kaufmann R, Bräutigam M, Wahn U. Treatment of infants with atopic eczema with pimecrolimus cream 1% improves parents' quality of life: a multicenter, randomized trial. *Pediatr Allergy Immunol* 2005; **16**: 527–33.
 41. Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. *Int J Clin Pract* 2006; **60**: 984–92.
 42. Chamlin SL, Chren MM. Quality-of-life outcomes and measurement in childhood atopic dermatitis. *Immunol Allergy Clin North Am* 2010; **30**: 281–8.
 43. Hanifin JM, Boguniewicz M, Eichenfield L, et al. A long-term study of safety and allergic comorbidity development in a randomized trial of pimecrolimus cream in infants with atopic dermatitis. *J Invest Dermatol* 2010; **130**: Abstract 328.
 44. Langley RG, Luger TA, Cork MJ, Schneider D, Paul C. An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance. *Dermatology* 2007; **215**(Suppl 1): 27–44.
 45. McCollum AD, Paik A, Eichenfield LF. The safety and efficacy of tacrolimus ointment in pediatric patients with atopic dermatitis. *Pediatr Dermatol* 2010; **27**: 425–36.
 46. Paul C, Cork M, Rossi AB, Papp KA, Barbier N, de Prost Y. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. *Pediatrics* 2006; **117**: e118–28.
 47. Eichenfield LF, Thaci D, de Prost Y, Puig L, Paul C. Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients. *Dermatology* 2007; **215**(Suppl 1): 3–17.
 48. Elidel (pimecrolimus cream 1%). US prescribing information. Novartis. 2010.
 49. Lakhanpaul M, Davies T, Allen BR, Schneider D. Low systemic exposure in infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%*. *Exp Dermatol* 2006; **15**: 138–41.
 50. Allen BR, Lakhanpaul M, Morris A, et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. *Arch Dis Child* 2003; **88**: 969–73.
 51. Harper J, Green A, Scott G, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. *Br J Dermatol* 2001; **144**: 781–7.
 52. Staab D, Pariser D, Gottlieb AB, et al. Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis—a multicenter, 3-week, open-label study. *Pediatr Dermatol* 2005; **22**: 465–71.
 53. Eichenfield LF, Ho V, Matsunaga J, Leclerc P, Paul C, Hanifin JM. Blood concentrations, tolerability and efficacy of pimecrolimus cream 1% in Japanese infants and children with atopic dermatitis. *J Dermatol* 2007; **34**: 231–6.
 54. Billich A, Aschauer H, Aszodi A, Stuetz A. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. *Int J Pharm* 2004; **269**: 29–35.
 55. Turpeinen M, Salo OP, Leisti S. Effect of percutaneous absorption of hydrocortisone

- on adrenocortical responsiveness in infants with severe skin disease. *Br J Dermatol* 1986; **115**: 475–84.
56. Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. *Dermatology* 2005; **211**: 174–87.
 57. Feldmann RJ, Maibach HI. Regional variation in percutaneous penetration of 14C cortisol in man. *J Invest Dermatol* 1967; **48**: 181–3.
 58. Papp KA, Breuer K, Meurer M, et al. Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. *J Am Acad Dermatol* 2005; **52**: 247–53.
 59. Stamatias GN, Nikolovski J, Luedtke MA, Kollias N, Wiegand BC. Infant skin microstructure assessed *in vivo* differs from adult skin in organization and at the cellular level. *Pediatr Dermatol* 2010; **27**: 125–31.
 60. Haapasaari KM, Risteli J, Karvonen J, Oikarinen A. Effect of hydrocortisone, methylprednisolone aceponate and mometasone furoate on collagen synthesis in human skin *in vivo*. *Skin Pharmacol* 1997; **10**: 261–4.
 61. Oikarinen A, Haapasaari KM, Sutinen M, Tasanen K. The molecular basis of glucocorticoid-induced skin atrophy: topical glucocorticoid apparently decreases both collagen synthesis and the corresponding collagen mRNA level in human skin *in vivo*. *Br J Dermatol* 1998; **139**: 1106–10.
 62. Protopic (tacrolimus 0.03% and 0.1% ointment). US prescribing information. Astellas. 2012.
 63. Krueger GG, Eichenfield L, Goodman JJ, et al. Pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adult and pediatric patients with moderate to severe atopic dermatitis. *J Drugs Dermatol* 2007; **6**: 185–93.
 64. Bieber T, Cork M, Ellis C, et al. Consensus statement on the safety profile of topical calcineurin inhibitors. *Dermatology* 2005; **211**: 77–8.
 65. Ormerod AD. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? *Br J Dermatol* 2005; **153**: 701–5.
 66. Ring J, Barker J, Behrendt H, et al. Review of the potential photo-carcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum. *J Eur Acad Dermatol Venereol* 2005; **19**: 663–71.
 67. US Department of Health and Human Services FaDA. Guidance for industry. M3 (R2) nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. Available at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073246.pdf>. (Accessed July 2014).
 68. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. *Am J Transplant* 2004; **4**: 222–30.
 69. Ganschow R, Schulz T, Meyer T, Broering DC, Burdelski M. Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients. *J Pediatr Gastroenterol Nutr* 2004; **38**: 198–203.
 70. Stockfleth E, Ulrich C, Meyer T, Christophers E. Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment. *Recent Results Cancer Res* 2002; **160**: 251–8.
 71. Ulrich C, Schmook T, Sachse MM, Sterry W, Stockfleth E. Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients. *Dermatol Surg* 2004; **30**: 622–7.
 72. Fitzsimmons W. Pharmacology of tacrolimus ointment. Available at http://www.fda.gov/ohrms/dockets/ac/00/slides/3659s1_02_fitzzimmons.ppt. (Accessed July 2014).
 73. Fonacier L, Spergel J, Charlesworth EN, et al. Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. *J Allergy Clin Immunol* 2005; **115**: 1249–53.
 74. Arellano FM, Wentworth CE, Arana A, Fernandez C, Paul CF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. *J Invest Dermatol* 2007; **127**: 808–16.
 75. Hui RL, Lide W, Chan J, Schottinger J, Yoshinaga M, Millares M. Association between exposure to topical tacrolimus or pimecrolimus and cancers. *Ann Pharmacother* 2009; **43**: 1956–63.
 76. Arellano FM, Arana A, Wentworth CE, Fernandez-Vidaurre C, Schlienger RG, Conde E. Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. *J Allergy Clin Immunol* 2009; **123**: 1111–6.
 77. Schneeweiss S, Doherty M, Zhu S, et al. Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma. *Dermatology* 2009; **219**: 7–21.
 78. Tennis P, Gelfand JM, Rothman KJ. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. *Br J Dermatol* 2011; **165**: 465–73.
 79. Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. *Dermatology* 2007; **214**: 289–95.
 80. Carr WW. Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. *Paediatr Drugs* 2013; **15**: 303–10.
 81. Lübke J. Secondary infections in patients with atopic dermatitis. *Am J Clin Dermatol* 2003; **4**: 641–54.
 82. Fleischer AB Jr, Ling M, Eichenfield L, et al. Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. *J Am Acad Dermatol* 2002; **47**: 562–70.
 83. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. *J Allergy Clin Immunol* 2003; **112**: S118–27.
 84. Luger T, De Raeve L, Gelmetti C, et al. Recommendations for pimecrolimus 1% cream in the treatment of mild-to-moderate atopic dermatitis: from medical needs to a new treatment algorithm. *Eur J Dermatol* 2013; **23**: 758–66.
 85. Carr J, Akram M, Sultan A, et al. Contamination of emollient creams and ointments with *Staphylococcus aureus* in children with atopic dermatitis. *Dermatitis* 2008; **19**: 282.
 86. Na'was T, Alkofahi A. Microbial contamination and preservative efficacy of topical creams. *J Clin Pharm Ther* 1994; **19**: 41–6.
 87. Silverberg JI, Lee-Wong M, Silverberg NB. Complementary and alternative medicines and childhood eczema: a US population-based study. *Dermatitis* 2014; **25**: 246–54.
 88. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies. *J Am Acad Dermatol* 2014; **71**: 116–32.
 89. Schneider L, Tilles S, Lio P, et al. Atopic dermatitis: a practice parameter update 2012. *J Allergy Clin Immunol* 2013; **131**: 295–9.
 90. Segal AO, Ellis AK, Kim HL. CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults. *Allergy Asthma Clin Immunol* 2013; **9**: 24.
 91. Jensen JM, Ahrens K, Meingassner J, et al. Differential suppression of epidermal antimicrobial protein expression in atopic dermatitis and in EFAD mice by pimecrolimus compared to corticosteroids. *Exp Dermatol* 2011; **20**: 783–8.